Abstract
"Indian Contract Manufacturing - A Hot Opportunity" is the recent report by
RNCOS that gives first hand information on the thriving contract manufacturing
market in India and the opportunities it is opening up for global players.
The Indian contract manufacturing market was worth US$ 874 Million in 2007.
Although this market presently occupies a fraction of the total global
opportunity, the future potential of the market seems immense. The Indian
contract manufacturing market, with its low cost advantage, strong chemistry
and reverse engineering capabilities, improving infrastructure and strong
incentives from the government, is expected to grow strongly in the next five
years. By 2012, the Indian industry is expected to grab nearly 8% of the total
global market.
The report comprehensively evaluates the contract manufacturing market in
India, analyzing its present market size, key segments, capabilities, and the
future direction of growth. It also gives a statistical and analytical insight
into the various factors vital for drug manufacturing, such as the competitive
advantage/disadvantage of India vis-à-vis developed countries on
various parameters such as cost, infrastructure, intellectual property and
infrastructure etc.
Key Findings
- Indian contract manufacturing market is expected to grow in excess of CAGR
37% between 2007 and 2012.
- Most companies presently outsource APIs and intermediates from India.
Moreover, India is also becoming a major hub for outsourcing formulations.
- Many Indian manufacturers have upgraded their manufacturing plants, which
has enabled India to have a number of plants certified by the FDA, EDQM and
various other regulatory agencies.
- The cost of secondary manufacturing in India is around 13%-15% of the cost
in the US, the UK and Germany, with companies making substantial savings on
costs of plant set up, labor and operations.
- India has more than four times the total drug manufacturing staff than the
US and more than 12 times that in the UK.
- Growth of the contract manufacturing market is expected to provide a major
boost to the pharma machinery market in India, which is expected to register
revenues up to US$ 822 Million by 2010.
- Strong appreciation of the Indian Rupee against the US Dollar is having a
detrimental effect on the profits of many Indian contract manufacturers.
Key Issues & Facts Analyzed
- Evaluation of the total size and growth rate of the contract manufacturing
market.
- Analysis of key segments.
- Evaluation of India' s capability in pharmaceutical manufacturing.
- Analysis of the total costs incurred while manufacturing a drug in India
(such as cost of land, construction, labor, utilities, freight etc).
- Analysis of the country' s pharma-related human resources.
- Study of the country' s pharma-related infrastructure.
- Analysis of the key opportunities created by the industry.
- Analysis of key players, including their business overview, key facts, and
financial information.
Research Methodology Used
Information Sources
Information has been sourced from books, newspapers, trade journals, and white
papers, industry portals, government agencies, trade associations, monitoring
industry news and developments, and through access to more than 3000 paid
databases.
Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear
regression analysis using software tools, judgmental forecasting and cause and
effect analysis.